Literature DB >> 2493806

Determination of the LDL receptor binding capacity of human lymphocytes by immunocytofluorimetric assay.

S Benhamamouch1, J P Kuznierz, G Agnani, D Marzin, J M Lecerf, J C Fruchart, V Clavey.   

Abstract

The determination of the LDL receptor binding capacity of human blood lymphocytes was assessed by indirect immunocytofluorimetric assay. To produce the maximal synthesis of the LDL receptor, the cholesterol efflux was enhanced by incubation of lymphocytes with HDL3 subfractions. The binding capacity of the LDL receptor was measured by incubation at 4 degrees C either with LDL and rabbit anti-LDL immunoglobulins or with peptide receptor antibody (ARP-Ig) raised against the NH2-terminal sequence of the LDL receptor. Thereafter complexes were incubated with fluorescein-labelled anti-rabbit immunoglobulin (FITC-Ig). Fluorescence flow cytometry was used to quantify the number of fluorescent lymphocytes and results were expressed as the percentage of lymphocytes with a fluorescent intensity above the threshold. Using preimmune rabbit immunoglobulin and then FITC-Ig, only 5-10% of cells were fluorescent. Neither LDL nor ARP-Ig could bind to homozygous familial hypercholesterolemia (FH) lymphocytes. Normal lymphocytes preincubated with HDL3 could bind LDL or ARP-Ig, the number of fluorescent cells being 59 and 39.2% respectively. Subjects with confirmed or suspected heterozygous FH demonstrated cell fluorescence at about half the normal level.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2493806     DOI: 10.1016/0005-2760(89)90062-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  European workshop on LDL receptor defects. European Working Group on Familial Hypercholesterolaemia.

Authors:  H Schuster; S Humphries
Journal:  Clin Investig       Date:  1994-11

2.  Use of the single-strand conformational polymorphism method to detect recurrent and novel mutations in the low-density lipoprotein receptor gene in patients with familial hypercholesterolaemia: detection of a novel mutation Asp200-->Gly.

Authors:  V Gudnason; Y T Mak; J Betteridge; S N McCarthy; S Humphries
Journal:  Clin Investig       Date:  1993-04

3.  Six DNA polymorphisms in the low density lipoprotein receptor gene: their genetic relationship and an example of their use for identifying affected relatives of patients with familial hypercholesterolaemia.

Authors:  S Humphries; L King-Underwood; V Gudnason; M Seed; S Delattre; V Clavey; J C Fruchart
Journal:  J Med Genet       Date:  1993-04       Impact factor: 6.318

4.  Phenotypic heterogeneity associated with defective apolipoprotein B-100 and occurrence of the familial hypercholesterolemia phenotype in the absence of an LDL-receptor defect within a Canadian kindred.

Authors:  J Davignon; R Dufour; M Roy; C Bétard; Y Ma; S Ouellette; L Boulet; S Lussier-Cacan
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

5.  Antipeptide antibody against the human low-density-lipoprotein receptor. Characterization and cross-reactivity with bovine lymphocytes.

Authors:  G Agnani; C Delpierre; S Benhamamouch; G Torpier; C Cachera; M Koffigan; A Tartar; J C Fruchart; V Clavey
Journal:  Biochem J       Date:  1989-11-01       Impact factor: 3.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.